Amir Bieber1,2, Abdallah Fawaz1,2, Irina Novofastovski1,2, Reuven Mader3,4. 1. From the Rheumatic Diseases Unit Ha'Emek Medical Center, Afula; The Technion Institute of Technology, Haifa, Israel. 2. A. Bieber, MD, Rheumatic Diseases Unit Ha'Emek Medical Center; A. Fawaz, MD, Rheumatic Diseases Unit Ha'Emek Medical Center; I. Novofastovski, MD, Rheumatic Diseases Unit Ha'Emek Medical Center; R. Mader, MD, Rheumatic Diseases Unit Ha'Emek Medical Center, and The Technion Institute of Technology. 3. From the Rheumatic Diseases Unit Ha'Emek Medical Center, Afula; The Technion Institute of Technology, Haifa, Israel. mader_r@clalit.org.il. 4. A. Bieber, MD, Rheumatic Diseases Unit Ha'Emek Medical Center; A. Fawaz, MD, Rheumatic Diseases Unit Ha'Emek Medical Center; I. Novofastovski, MD, Rheumatic Diseases Unit Ha'Emek Medical Center; R. Mader, MD, Rheumatic Diseases Unit Ha'Emek Medical Center, and The Technion Institute of Technology. mader_r@clalit.org.il.
Abstract
OBJECTIVE: Antitumor necrosis factor-α (anti-TNF-α) therapy is the most prescribed biologic agent therapy in rheumatology and gastroenterology. However, a number of serious side effects have been reported with these drugs. Only a handful of cases of new-onset inflammatory bowel disease (IBD), mostly in children diagnosed with juvenile idiopathic arthritis (JIA), have been reported during anti-TNF-α therapy. We present 3 cases of adult IBD following anti-TNF-α therapy and a literature review on this topic. METHODS: We searched PubMed MESH for all relevant terms, papers were reviewed, and patient-specific data were extracted. Relevant clinical data were calculated and presented. RESULTS: The PubMed search resulted in 137 articles, of which 11 articles and 4 cited publications were included in our analysis. We found 53 cases of IBD after anti-TNF-α therapy reported in the literature; most of them were case series collected retrospectively from national databases or studies. Almost all the patients developed IBD after the introduction of etanercept (ETN); 2 patients with rheumatoid arthritis were also included. The average age at IBD onset was 17.3 years and the average time from ETN introduction to IBD onset was 27 months (± 24). Gastrointestinal symptoms have been reported as improving or subsiding in most of the patients after discontinuing ETN. CONCLUSION: Although this manifestation is not common, it should be taken into consideration as an adverse effect of ETN. Rheumatologists, and in particular rheumatologists treating adult patients, should be aware of this possible complication. Further investigation about the pathogenic process underlying this phenomenon is warranted.
OBJECTIVE: Antitumor necrosis factor-α (anti-TNF-α) therapy is the most prescribed biologic agent therapy in rheumatology and gastroenterology. However, a number of serious side effects have been reported with these drugs. Only a handful of cases of new-onset inflammatory bowel disease (IBD), mostly in children diagnosed with juvenile idiopathic arthritis (JIA), have been reported during anti-TNF-α therapy. We present 3 cases of adult IBD following anti-TNF-α therapy and a literature review on this topic. METHODS: We searched PubMed MESH for all relevant terms, papers were reviewed, and patient-specific data were extracted. Relevant clinical data were calculated and presented. RESULTS: The PubMed search resulted in 137 articles, of which 11 articles and 4 cited publications were included in our analysis. We found 53 cases of IBD after anti-TNF-α therapy reported in the literature; most of them were case series collected retrospectively from national databases or studies. Almost all the patients developed IBD after the introduction of etanercept (ETN); 2 patients with rheumatoid arthritis were also included. The average age at IBD onset was 17.3 years and the average time from ETN introduction to IBD onset was 27 months (± 24). Gastrointestinal symptoms have been reported as improving or subsiding in most of the patients after discontinuing ETN. CONCLUSION: Although this manifestation is not common, it should be taken into consideration as an adverse effect of ETN. Rheumatologists, and in particular rheumatologists treating adult patients, should be aware of this possible complication. Further investigation about the pathogenic process underlying this phenomenon is warranted.